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Intimin is the primary adhesin of Escherichia coli O157:H7, the most common infectious cause of bloody
diarrhea in the United States and the leading cause of acute kidney failure in children who develop hemolytic
uremic syndrome. Cattle are the primary reservoir of E. coli O157:H7. Indeed, most cases of E. coli O157:H7
infection in the United States occur after ingestion of contaminated undercooked hamburger or produce that
had contact with bovine manure. Because intimin is required for persistent colonization of neonatal calves and
adult cattle, we hypothesized that an intimin-based vaccination strategy in calves would reduce colonization of
cattle with E. coli O157:H7. To test this concept in a small-animal model, we developed transgenic tobacco plant
cells that express the carboxy-terminal host cell-binding domain of E. coli O157:H7 intimin. Mice were either
immunized intraperitoneally with intimin expressed from the plant cells, fed transgenic plant cells, or both.
Here we show that these mice generated an intimin-specific mucosal immune response when primed paren-
terally and then boosted orally and also exhibited a reduced duration of E. coli O157:H7 fecal shedding after
challenge.
Escherichia coli O157:H7 is the most common cause of
bloody diarrhea, or hemorrhagic colitis, in the United States,
with an estimated incidence of 73,480 cases per annum (7, 34).
Moreover, hemolytic uremic syndrome, a sequela of E. coli
O157:H7 infection, is the most frequent basis for acute kidney
failure in U.S. children (7). These organisms are typically
transmitted directly or indirectly from infected cattle to hu-
mans. Both beef and dairy cattle can be sporadically and
asymptomatically colonized with E. coli O157:H7 and shed the
bacteria, which can survive in broad ecological niches beyond
the bovine gastrointestinal tract, into the environment in their
feces (10, 17, 25, 28). Moreover, contacts with the farming
environment and livestock density are major risk factors for
human infection and disease caused by E. coli O157:H7. Many
of the foods implicated in human disease are of bovine origin
or are food or water that have come into contact with contam-
inated meat or bovine fecal material (14, 43).
A number of investigators have concluded that a decrease in
the amount of E. coli O157:H7 shed as well as in the number
of cattle that excrete the serotype could cause a significant
reduction in the prevalence of the bacteria in cattle and the
farm environment. The hypothesis that vaccination of cattle or
treatment of the animals with an agent to diminish the level of
colonization and shedding of E. coli O157:H7 could potentially
lead to a decline in the incidence of human E. coli O157:H7-
related disease (17, 22, 47) was suggested by the findings from
a stochastic simulation model designed by Jordan et al. (22).
Based on this idea, B. Finlay’s group, our laboratory, and
others have begun to design and/or test E. coli O157:H7 vac-
cine protocols for use in cattle. Indeed, Finlay and colleagues
have initiated field studies of E. coli O157:H7 secreted prod-
ucts as a subcutaneously administered bovine vaccine [B. Fin-
lay, Abstr. 5th Int. Symp. “Shiga toxin (verocytotoxin)-produc-
ing Escherichia coli infections,” abstr. p. 23, 2003; R. Moxley,
D. Smith, T. Klopfenstein, G. Erickson, J. Folmer, C. Macken,
S. Hinkley, A. Potter, and B. Finlay, Abstr. 5th Int. Symp.
“Shiga toxin (verocytotoxin)-producing Escherichia coli infec-
tions,” abstr. p. 23, 2003].
We selected a different immunogen, expression system, and
route of administration for proof of concept studies to assess,
in a small-animal model, the feasibility of an E. coli O157:H7
vaccine for cattle. For our vaccine candidate, we chose intimin,
an outer membrane protein of E. coli O157:H7 that is required
for attaching and effacing lesion formation as well as for bac-
terial adherence to mammalian cells and the intestinal mucosa
of calves, piglets, and ferrets (8, 21, 32, 46). Intimin is the
product of the eae (E. coli attach and efface) gene, which is
contained within an approximately 43-kb pathogenicity island
called the locus of enterocyte effacement (23, 24, 36). The
carboxy-terminal portion of intimin binds the bacterium-en-
coded translocated intimin receptor (Tir) and a host cell re-
ceptor, nucleolin, to mediate intimate attachment of the bac-
teria to the eucaryotic cell surface (11, 12, 38). The reasons we
consider intimin an attractive candidate for an E. coli O157:H7
antitransmission vaccine for cattle are based on both in vitro
and in vivo studies. Specifically, members of our laboratory
previously found that antibodies against the carboxy-terminal
third of the molecule block adherence of wild-type E. coli
O157:H7 to HEp-2 cells (13, 33). In addition, our laboratory,
with E. Dean-Nystrom’s group, showed that colostrum from
pigs immunized with intimin isolated from E. coli O157:H7
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contains anti-intimin antibodies that can protect suckling pig-
lets from colonization with E. coli O157:H7 (13). These tissue
culture experiments and passive transfer studies suggest that
antibodies specific to intimin play an important role in blocking
adherence of the bacterium to host cells and can protect the
host from E. coli O157:H7-mediated disease.
For delivery of intimin as a vaccine for cattle, we sought an
oral inoculation system to facilitate induction of mucosal an-
tibodies and for ease of administration. Therefore, we elected
to use a transgenic plant cell system for intimin expression,
with the ultimate goal of moving the antigen into whole-plant
expression and delivery systems. Transgenic plants offer the
flexibility to function as low-cost, efficient, and practical vac-
cine antigen oral delivery systems to stimulate mucosal immu-
nity or to boost and shift initial immunity to a mucosal anti-
body response (27, 44). Indeed, transgenic plants have already
been used as successful vaccine antigen production and deliv-
ery systems (18, 29, 30, 40). The vaccine antigens expressed by
plants include hepatitis B surface antigen (26, 31, 42), entero-
toxigenic E. coli heat-labile toxin B subunit (LT-B) (18, 27, 30,
40), Norwalk virus capsid protein (29, 41), cholera toxin B
subunit (2, 3), and many others. For this study, we created
carboxy-terminal third of intimin-expressing plant cells and
evaluated the capacity of this transgenic material to induce
adherence-blocking antibodies and to reduce levels and/or
time of E. coli O157:H7 fecal shedding in a mouse model of
intimin-dependent colonization.
MATERIALS AND METHODS
Bacterial strains, plasmids, and media. The bacterial strains and plasmids
used in this study are summarized in Tables 1 and 2, respectively. Enterohem-
orrhagic E. coli (EHEC) O157:H7 strain 86-24 (15) was isolated in 1986 from a
patient in Seattle, Wash., and was kindly provided by Phil Tarr. EHEC O157:H7
strain 86-24 that expresses the green fluorescent protein arabinose-inducible
plasmid p166 was used to visualize bacteria in the HEp-2 cell adherence assay, as
previously described (13, 38). A streptomycin-resistant derivative of strain 86-24
(called 86-24 Strr [35]) and its isogenic, intimin-negative mutant strain 86-24
eae10 (called 86-24 Strr eae10 [32]) were used to distinguish EHEC O157:H7
from other fecal bacteria during the colonization assay by plating on sorbitol-
MacConkey agar with 100 g of streptomycin per ml. In addition, several sor-
bitol-negative colonies from different mice at each collection time point were
tested by slide agglutination with O157 antiserum (Difco Laboratories, Sparks,
Md.) to confirm that the colonies were of the O157 serogroup. All mice were free
of Strr, O157 agglutination-positive colonies prior to challenge. Agrobacterium
tumefaciens strain EHA105, plasmids with plant-specific expression components
(pBTI210.3, pBTI210.4, and pIBT210), and the binary vector pGPTV-Kan were
provided by the Boyce Thompson Institute for Plant Research (Cornell Univer-
sity, Ithaca, N.Y.). All E. coli strains and clones were grown in Luria-Bertani
(LB) broth or on LB agar. Prior to plant cell transformation, Agrobacterium
strains were grown in YM broth (0.4 g of yeast extract, 10 g of mannitol, 0.1 g of
NaCl, 0.2 g of MgSO4 · 7H2O, 0.5 g of K2HPO4 per liter). Antibiotics were added
as needed for selection at the following concentrations: ampicillin, 100 g/ml;
kanamycin, 50 g/ml; carbenicillin, 100 g/ml. Plasmid DNA was isolated by the
Miniprep procedure (Qiagen, Valencia, Calif.). Restriction enzymes were pur-
chased from New England Biolabs (Beverly, Mass.), and restriction enzyme-
digested DNA fragments were purified by agarose gel electrophoresis and eluted
from the gel with Geneclean spin columns and reagents (Bio 101, Carlsbad,
Calif.). T4 DNA ligase was purchased from U.S. Biochemicals (Cleveland,
Ohio). PCRs were done with AmpliTaq (Roche, Branchburg, N.J.) and Pfu
Turbo (Stratagene, La Jolla, Calif.) polymerases in an MJ Research Minicycler
(Watertown, Mass.). Sequencing was performed with the ABI Big Dye sequenc-
ing kit (Applied Biosystems, Inc., Foster City, Calif.). Products were separated
and analyzed by the Biomedical Instrumentation Center at Uniformed Services
University of the Health Sciences with Applied Biosystems sequencer model 377
or 3100. Sequence results were compared to published sequences by use of the
Wisconsin Sequence Analysis package from the Genetics Computer Group, Inc.
(Madison, Wis.).
Optimization of eae (nucleotides 1959 to 2804) for plant expression. Thirteen
independent changes were made to the nucleotide sequence of the intimin gene
from pMW103 with the QuikChange site-directed mutagenesis kit (Stratagene).
The seven sets of oligonucleotides listed in Table 3 were designed according to
the protocol listed in the QuikChange manual. The initial mutagenesis reaction
was done with 50 ng of pMW103 and 125 ng of each primer from primer set 1 in
a total volume of 50 l. In addition, 1 l of Pfu Turbo polymerase was added to
TABLE 1. Bacterial strains used in this study
Strain Relevant characteristics Reference orsource
86-24 E. coli O157:H7, eae
positive
15
86-24 GFP E. coli O157:H7(p166) 38
86-24 Strr E. coli O157:H7, Strr 35
86-24 eae10 Strr E. coli O157:H7, eae
negative, Strr
32
DH5 E. coli cloning host,
recA
16
XL-1 Blue E. coli cloning host,
recA lacIq
6; Stratagene
A. tumefaciens EHA105 Plant transformation
strain
20
TABLE 2. Plasmids used in this study
Plasmid Relevant characteristicsa Reference or source
Intimin plasmids
pMW103 Truncated eae (bp 1959–2804) in pQE31 (Qiagen) 13
pNR37 eae from pMW103, plant optimized This study
Plant expression vectors
pIBT210 CaMV 35S promoter, TEV 5 UTR, Vsp 3 UTR 18
pBTI210.3 CaMV 35S promoter, TMV 5 UTR, Vsp 3 UTR Hugh Mason, while at Boyce Thompson
Institute for Plant Research
pBTI210.4 CaMV 35S promoter, TEV 5 UTR, VspB 3 UTR,
with plant-specific signal peptide sequence
Hugh Mason, while at Boyce Thompson
Institute for Plant Research
pGPTV-Kan Binary vector, Kanr 4
Plant-specific intimin expression vectors
pNR49 eae from pNR37 with signal peptide sequence from
pBTI210.4
This study
pNR50 eae from pNR37 This study
VOL. 72, 2004 ORAL INTIMIN VACCINE REDUCES E. COLI O157:H7 SHEDDING 169
each reaction tube immediately prior to placing the sample tubes into the Mini-
cycler. The samples were subjected to a 30-s hot start at 95°C and then 12 cycles
of 95°C for 30 s, 55°C for 60 s, and 68°C for 12 min. After the cycles were
completed, each reaction mixture was digested with DpnI, and 1 to 5 l of the
digested reaction was transformed into the supercompetent cells provided with
the kit according to the protocol outlined in the QuikChange manual. The
transformed cells were plated on LB agar with ampicillin. Several ampicillin-
resistant colonies were selected, and 3 ml of overnight LB broth culture was
prepared from each colony. Bacteria were then harvested by centrifugation, and
plasmid DNA was purified from the pelleted organisms. The eae sequences were
amplified by PCR from the plasmids, and the PCR products were then eluted
from an agarose gel and sequenced. Clones for which the sequence of the
mutated, PCR-amplified eae gene had been confirmed were used in the next
round of mutagenesis with the next set of mutagenesis primers. The final plant-
optimized intimin clone from pMW103 (13) that contained all 13 nucleotide
changes was called pNR37. The intimin protein encoded by this gene has an
amino-terminal histidine tag and consists of the carboxy-terminal 261 amino
acids of intimin from E. coli O157:H7 (Int261).
Plant expression plasmid construction. The nucleotide sequence for the VspA
signal peptide was amplified by PCR from pHB306 (37). A fragment that con-
tained the nucleotide sequences for the tobacco etch virus (TEV) 5 untranslated
region (UTR) and the VspA signal peptide (encodes MAMKVLVFFVATIL
VAWGA) was ligated into the XhoI and SacI sites of pIBT210 (18) to make
pBTI210.4. Plasmid pBTI210.4 codes for a plant-specific signal peptide 5 to a
SacI site, a cauliflower mosaic virus (CaMV) 35S promoter, the TEV 5 UTR,
and a VspB 3 flank. The gene for Int261 was amplified by PCR from pNR37 to
include flanking SacI sites; this fragment was cloned into the SacI site of
pBTI210.4. The EcoRI-HindIII fragment of the resultant plasmid was then
cloned into pGPTV-Kan (4) to create pNR49.
Plasmid pBTI210.3 was created by digestion of pHB211.1 (37) with NcoI. This
restriction enzyme-digested DNA was 3 end-filled with Klenow polymerase and
then further digested with XhoI and mung bean nuclease. The resultant blunt-
ended vector fragment was ligated to generate pHB211. The HindIII-NcoI frag-
ment of pHB211 that contained the sequences for the CaMV 35S promoter fused
to the TMV 5 UTR was ligated into pIBT210 to create pBTI210.3. Site-directed
mutagenesis was used to introduce an NcoI site 5 of the histidine-tagged Int261
gene from pNR37. The plasmid was cut with NcoI and KpnI, and the fragment
that contained the Int261 gene was cloned into pBTI210.3. The EcoRI-HindIII
fragment of the resultant plasmid was cloned into pGPTV-Kan to create pNR50.
NT-1 cell culture and transformation. Nicotiana tabacum cv. Bright Yellow 2
(NT-1) cells (1) were grown at 25°C on a rotary shaker (150 rpm) in 40 ml of NT
medium [Murashige minimal organics medium (Invitrogen Life Technologies,
Carlsbad, Calif.), 30 g of sucrose per liter, 3 M thiamine, 0.58 mM myoinositol,
1.3 mM KH2PO4, 1 M 2,4-dichlorophenoxyacetic acid (Sigma, St. Louis, Mo.),
2.5 mM 2(N-morpholino)ethanesulfonic acid, pH 5.7]. These cells were subcul-
tured (1 part cells to 19 parts NT medium) every 7 days. To facilitate transfor-
mation, binary vectors of interest were introduced into A. tumefaciens EHA105
by electroporation. Agrobacterium strains that contained the construct of interest
were used to transform NT-1 cells as previously described (1). The NT-1 cells
were kindly provided by the Boyce Thompson Institute for Plant Research.
Immunoblot analysis of Int261 expressed in plant cells. A small amount of
plant cell material (0.03 g), resuspended in an extraction buffer (25 mM sodium
phosphate [pH 6.6], 100 mM NaCl, 10 mM EDTA, 0.1% Triton X-100, 10 g of
leupeptin per ml, and 50 mM sodium ascorbate), was disrupted by sonication
(25-s pulse; 5 s on, 10 s off). The lysed material was clarified by centrifugation
(12,000  g, 3 min, 4°C), and proteins in the extract were subjected to sodium
dodecyl sulfate-polyacrylamide gel electrophoresis. The separated proteins in the
Tris-glycine-sodium dodecyl sulfate-polyacrylamide gels were transferred onto
nitrocellulose and probed with anti-intimin polyclonal antibodies. Antigen
amounts were quantified by comparing the Western blot band intensity to that of
a known concentration of control purified Int261 (35 kDa) from pMW103 (13)
by use of the NIH Image (v. 1.61) program (38).
Mouse feeding assay. NT-1 cells or transgenic NT-1 cell clones that expressed
Int261 were grown in 40-ml suspension cultures to confluence (about 7 days). The
cells were pelleted by gentle centrifugation, and culture medium was removed
with a pipette. Five grams of NT-1 cell material was divided into aliquots in small,
individual plastic weigh dishes, and 0.5 g of sucrose was added to each sample.
A 7.5-g dose of purified cholera toxin (CT) (Sigma) was also added to appro-
priate samples to serve as an oral adjuvant. The addition of this dose of CT did
not appear to have any detrimental effects on the mice (i.e., loose stool or
diarrhea). Female BALB/c mice of 16 to 18 g were made to fast overnight before
they were allowed to eat the plant material ad libitum. All of the plant material
was usually consumed within 8 h. The mice were bled by a tail vein cut, and fecal
pellets were collected both prior to and after feeding. Blood samples were
allowed to clot at room temperature for 15 min and centrifuged at 10,000  g for
10 min to pellet red blood cells. A second, 2-min centrifugation step was used to
further clarify each serum sample. These clarified samples were then stored at
	20°C until assayed. Fecal samples were frozen, lyophilized overnight, and then
homogenized in phosphate-buffered saline (PBS), pH 7.2 (for every 15 pellets,
0.8 ml of PBS was used). The resuspended fecal material was centrifuged for 5
min, and each supernatant was then transferred to a clean tube and stored at
	20°C until assayed. Mice immunized intraperitoneally (i.p.) with purified His-
tagged Int261 (from pMW103 [13]) plus TiterMax (TiterMax USA Inc., Norcross,
Ga.) (20 g on day 0 and 10 g on days 7 and 14) served as the positive control.
ELISA. For measurement of anti-intimin antibodies, an enzyme-linked immu-
nosorbent assay (ELISA) was developed. For that purpose, U-bottomed 96-well
microtiter plates were coated with 50 ng of purified histidine-tagged Int261 from
pMW103 (13) per well. Serum samples were diluted from a titer of 1:50 to
1:781,250 and fecal pellet extracts were diluted from 1:50 to 1:3,200 and incu-
bated overnight at 4°C. The plates were washed, and goat anti-mouse immuno-
globulin G (IgG) (1:3,000) or goat anti-mouse IgA (1:3,000) conjugated to
alkaline phosphatase was added to the appropriate plates. The plates were then
incubated at room temperature for 1 h. The antigen-antibody reactions were
detected colorimetrically by incubation with tetramethylbenzidine peroxidase
substrate (Bio-Rad) for 15 min followed immediately by measurement of the
absorbance at 600 nm with an ELx800 microtiter plate reader (Bio-Tek Instru-
ments Inc., Winooski, Vt.). The titer was defined as the reciprocal of the highest
dilution of serum or fecal extract that gave an absorbance reading above both
background and preimmune levels. Mice were considered responders if they had
detectable titers in serum or fecal material at the last collection point. Mice with
no titer or that lost titer by the last collection point were called nonresponders.
The geometric mean of the responders’ titers was used to determine the mean
response per group.
TABLE 3. Oligonucleotide sets for eae (nucleotides 1959 to 2804) plant expression optimization by QuikChange site-directed mutagenesis
Oligonucleotide Sequencea
1-forward ................................................................................GGGTCAGCCAGTTAACAACCAATCCGTTACATTCTCAACAAACTTTGG
1-reverse .................................................................................CCAAAGTTTGTTGAGAATGTAACGGATTGGTTGTTAACTGGCTGACCC
2-forward ................................................................................GGCTGCAATATGGTCAATTTAAACTGAAAGCAAGCGG
2-reverse .................................................................................CCGCTTGCTTTCAGTTTAAATTGACCATATTGCAGCC
3-forward ................................................................................GGGAAAGTCACTTTGAATGGTAAAGGCTCTGTCGTAATTAAAGCC
3-reverse .................................................................................GGCTTTAATTACGACAGAGCCTTTACCATTCAAAGTGACTTTCCC
4-forward ................................................................................GGTGATAAGCAAACAGTAAGTTACACTATCAAGGCACCGTCG
4-reverse .................................................................................CGACGGTGCCTTGATAGTGTAACTTACTGTTTGCTTATCACC
5-forward ................................................................................GCTATGTCCATTTGCAAAAACTTGTTACCATCCACACAGACGG
5-reverse .................................................................................CCGTCTGTGTGGATGGTAACAAGTTTTTGCAAATGGACATAGC
6-forward ................................................................................GGTATTGTCAGATATCTATGACTCATGGGGGGCTGCAAACAAGTATAGCC
6-reverse .................................................................................GGCTATACTTGTTTGCAGCCCCCCATGAGTCATAGATATCTGACAATACC
7-forward ................................................................................GGATTAAACAGACATCTAGTGAGCAACGTTCTGGAGTATCAAGC
7-reverse .................................................................................GCTTGATACTCCAGAACGTTGCTCACTAGATGTCTGTTTAATCC
a Sites of mutagenesis are indicated in bold.
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E. coli O157:H7 colonization of mice. Female BALB/c mice of 16 to 18 g
(Charles River Laboratories, Inc.) were made to fast overnight and fed a total
inoculum of 108 to 109 CFU of E. coli O157:H7 strain 86-24 Strr or 86-24 Strr
eae10 in each of two doses administered 4 h apart. Fecal pellets were collected
daily from individual mice and weighed, and serial dilutions of fecal pellet
homogenates were prepared in PBS. These homogenates were plated on sorbi-
tol-MacConkey agar (45) with 100 g of streptomycin per ml to determine the
CFU per gram of feces and the duration of colonization.
Statistical methods. Determination of the mean duration of colonization and
statistical comparison of the duration of colonization among mouse groups were
done with the SPSS 11.0 statistical package. The log-rank test was used to
determine the statistical significance of the difference in duration of colonization
among the mouse groups.
RESULTS
Construction of NT-1 plant cells that express the carboxy-
terminal third of intimin. We began by generating intimin-
expressing transgenic plant cells. For this purpose, we con-
structed two expression vectors (pNR49 and pNR50) with the
eae gene from pMW103 (13) that we had optimized for ex-
pression in plants (Fig. 1A). The intimin protein encoded by
this gene has an amino-terminal histidine tag and consists of
the carboxy-terminal 261 amino acids of intimin from E. coli
O157:H7 (Int261). The carboxy terminus of intimin is the cell-
binding domain (11, 12). A. tumefaciens EHA105 was used to
transfer the DNA for Int261 expression from the binary vectors
into the nicotine-free tobacco cell line NT-1 (1, 20). Kanamy-
cin-resistant calli were selected, and Int261 expression was as-
sayed by Western blot analysis (Fig. 1B).
Two independent transgenic NT-1 cell clones were used for
the experiments described below. Clone 20 (CSP20) was cre-
ated by transformation of NT-1 cells with pNR49. This clone
expressed Int261 with a plant-specific signal peptide (35 kDa)
and produced 10 to 13 g of Int261 per g of total plant material.
Clone 34 (C34) was generated by transformation of NT-1 cells
with pNR50. This clone expressed Int261 without a signal pep-
tide and produced 3 g of Int261 (35 kDa) per g of total
plant material (Fig. 1B).
Glycosylation of Int261 expressed with a plant signal pep-
tide. Although CSP20 expressed four times more antigen than
C34, CSP20 accumulated higher-molecular-weight bands over
time in culture (Fig. 2A). Moreover, this plant material, when
fed to mice, elicited an antibody response (as assessed by
ELISA) that recognized Int261 purified from that clone, but not
from bacterial cells. In addition, mice fed CSP20 were colo-
nized at the same level and for the same duration as mice fed
plant cells alone when challenged with wild-type E. coli
O157:H7 strain 86-24 (data not shown). Based on these find-
ings, we speculated that the higher-molecular-weight bands
noted in Fig. 2A might represent a glycosylated form of Int261
that was recognized by the murine host differently than the
protein made by bacteria. To test this theory, Int261 from
CSP20 was purified by nickel affinity chromatography and then
treated with trifluoromethanesulfonic acid (TFMS) (Glyco-
Free deglycosylation kit from Glyco, Inc). TFMS nonselec-
tively removes both N- and O-linked glycans from glycopro-
teins without altering the primary protein structure. The
appearance of a band with a molecular mass consistent with
that of control Int261 (35 kDa, purified from pMW103 [13] by
nickel affinity chromatography) after treatment with TFMS
FIG. 1. Expression of Int261 in NT-1 cells. (A) The Int261 plant transformation vectors pNR50 and pNR49 are comprised of an Int261 expression
cassette with a CaMV 35S promoter and a neomycin phosphotransferase II expression cassette for detection of kanamycin resistance in successfully
transformed clones. A VspA signal peptide was included in pNR49 to increase protein expression. (B) Immunoblot analysis of Int261 expressed
with or without the signal peptide. Int261 (35 kDa) purified by nickel affinity chromatography from pMW103 (13) (75 ng) served as the positive
control (lanes 1 and 4). NT-1 cells transformed with pGPTV-Kan vector only did not express Int261 (lane 3). NT-1 cells transformed with pNR49
(CSP20) expressed several intimin-specific bands (lane 2). NT-1 cells transformed with pNR50 (C34) from both plate (lane 5) and broth (lane 6)
cultures expressed a single intimin-specific band (35 kDa).
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strongly suggested that Int261 from CSP20 was in fact glycosy-
lated (Fig. 2B). We noted that the Int261 sequence contains two
potential asparagine-linked glycosylation sites (NQS and NTS)
that could be modified by glycosylation in this endoplasmic
reticulum-targeted form. The two higher-molecular-weight
bands observed for Int261 from CSP20 could result from gly-
cosylation of either one or both of these N-linked sites. Since
this probable glycosylation of Int261 in CSP20 adversely af-
fected the immune response to this antigen, we elected to
proceed with the C34 clone that expressed Int261 without the
addition of a signal peptide and in an apparently unglycosy-
lated state (Fig. 1B).
Generation of intimin-specific serum and fecal antibodies.
We tested several different vaccination strategies with C34 in
mice. The vaccine protocols and the serum (IgG) and fecal
(IgA and IgG) ELISA results are summarized in Table 4. To
maximize the immune response to orally administered Int261,
we tried a priming-boosting protocol (groups E and F) similar
to that used to elicit an enhanced immune response to the B
subunit pentamers of E. coli LT-B (27). Five of ten mice
primed by injection of purified Int261 from C34 and then fed
nontransgenic plant material developed an intimin-specific fe-
cal antibody response. These results suggest that even a single
inoculation with Int261 from C34 can elicit a mucosal antibody
response to intimin. Seven of ten mice primed by injection of
Int261 from C34 and then boosted by feeding with C34 (with
CT as an oral adjuvant) produced an intimin-specific fecal IgA
response. The Fisher’s exact test was used to compare percent-
ages of responders, and we found that both groups E and F had
a significantly higher number of fecal IgA responders than the
negative control group, B (P 
 0.033 and 0.003, respectively).
There was no significant difference in percentages of respond-
ers between groups E or F and group A (P 
 0.175 and 1.000,
respectively). In addition, 3 of 10 mice developed an IgG
response in serum, and serum samples from these mice
blocked adherence of wild-type E. coli O157:H7 to HEp-2 cells
compared to preimmune serum controls (data not shown).
Colonization of mice by E. coli O157:H7 is dependent on
intimin. We determined that E. coli O157:H7 strain 86-24 Strr
(35) reproducibly colonized female BALB/c mice at modest
FIG. 2. Immunoblot analysis of Int261 from NT-1 cell clone CSP20. (A) The higher-molecular-weight, intimin-specific bands (arrow) accumu-
lated as the culture aged. Lane 1, control Int261 purified from pMW103 (13); lane 2, Int261 from CSP20 in continuous culture for over 6 months.
(B) Int261 from CSP20 treated with TFMS. Int261 purified by Ni affinity chromatography from pMW103 (13) shows the expected size of
approximately 35 kDa (lane 1). Plant cell sonic extracts from NT-1 cells alone did not produce Int261 (lane 2). Int261 from CSP20 was purified by
nickel affinity chromatography and showed two higher-molecular-weight intimin-specific bands compared to the control (lane 3). When material
from lane 3 was treated with TFMS, a single band of approximately 35 kDa appeared that was consistent with the size of the control Int261 band
(lane 4).
TABLE 4. Immunogenicity in BALB/c mice of NT-1 cells that express Int261
Group, immunization protocol Vaccination method IgG titer (no. of responders/total)in seruma
Titer (no. of responders/total)
in fecesa
A, i.p. Int261 from pMW103 20 g of Int261 plus TiterMax i.p. on day 0, 10 g of
Int261 plus TiterMax i.p. on days 10 and 20
300,000 (10/10)b 560 (8/10) (IgA only)c
B, Fed NT-1 cells only 5 g of NT-1 cells fed on days 0, 7, and 14 50 (0/10) 50 (0/10)
C, Fed C34 cells only 5 g of C34 with 15 g of Int261 fed on days 0, 7, and 14 50 (0/10) 340 (4/10) (IgG and IgA)
D, Fed C34 cells with CTd 5 g of C34 with 15 g of Int261 plus CT fed on days 0,
7, and 14
50 (0/10) 280 (6/10) (IgG and IgA)
E, i.p. Int261 from C34, fed NT-
1 cells only
15 g of Int261 from C34 plus TiterMax i.p. on day 0;
5 g of NT-1 cells fed on days 7 and 14
50 (1/10) 150 (5/10) (IgA only)
F, i.p. Int261 from C34, fed C34
cells with CT
15 g of Int261 from C34 plus TiterMax i.p. on day 0;
5 g of C34 cells with 15 g of Int261 plus CT fed on
days 7 and 14
80 (3/10) 180 (7/10) (IgA only)
a Serum and fecal pellet extracts were collected throughout the experiment and were evaluated by ELISA for the presence of antibodies against Int261. The titer was
defined as the geometric mean of the reciprocal of the highest dilution that gave an absorbance (A600) above both preimmune and background levels. Responders were
defined as mice that had a detectable titer at the final sample collection point (7 days after the final feeding or injection).
b Significantly higher IgG titer in serum and number of responders than other groups (P  0.0001, two-sided t test; P  0.003, Fisher’s exact test).
c IgA titer in feces was significantly different than that for groups E and F (P 
 0.019 and 0.013, respectively [two-sided t test]). The number of fecal IgA responders
was significantly different from that for groups E and F (P 
 0.175 and 1.000, respectively [Fisher’s exact test]).
d CT, cholera toxin (7.5 g; Sigma).
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levels for approximately 10 days (mean, 6.4 to 13.4 days for
unimmunized mice). Furthermore, in an experiment limited to
7 days, E. coli O157:H7 86-24 Strr colonized BALB/c mice a
mean of 6.4 days, whereas the intimin-negative mutant 86-24
Strr eae10 showed a statistically significant reduction in the
duration of colonization (mean, 3.2 days; P  0.005; log-rank
test).
Challenge of vaccinated mice with E. coli O157:H7. With this
intimin-dependent mouse model of E. coli O157:H7 coloniza-
tion, we orally infected the same groups of immunized mice
described in Table 4 with strain 86-24 Strr. We found that mice
primed with an i.p. injection of Int261 from C34 and then fed
homologous C34 plant material with CT showed a statistically
significant (P  0.002; log-rank test) reduction in the duration
of colonization (as measured by fecal shedding) compared to
the negative control mice that were fed nontransgenic NT-1
cells only (Fig. 3). The mice that were primed and boosted with
Int261 from transgenic plant material also exhibited a statisti-
cally significant decrease in the duration of bacterial coloniza-
tion compared to mice that were only immunized i.p. with
Int261 from C34 and then boosted with nontransgenic plant
material (P 
 0.033; log-rank test). These results suggest that
the feeding of transgenic, Int261-expressing plant material plays
a significant role in boosting the immune response to Int261
and in reducing the duration of bacterial colonization. The
positive control mice, injected i.p. three times with highly pu-
rified Int261 from pMW103 (13), also displayed a statistically
significant reduction in the duration of colonization versus the
negative control (P  0.002; log-rank test). There was no
difference in the duration of shedding between the positive
control immunization method and the priming-boosting pro-
tocol with oral delivery of transgenic plant material that ex-
pressed Int261 as a boost. This last observation suggests that
immunization with a plant-based oral vaccine can induce an
immune booster response sufficient to provide protection from
a challenge with wild-type E. coli O157:H7.
DISCUSSION
Many pathogens infect or invade via mucosal surfaces, so the
capacity of plant-based vaccines to induce mucosal immunity is
a great advantage. Plant cells act as a natural microencapsu-
lation system to protect the vaccine antigens from being de-
graded in the upper digestive tract before they can reach the
gut-associated lymphoid tissue. Recent studies suggest that
plant-based oral vaccines can significantly boost mucosal im-
mune responses primed by parenteral injection (27, 44). Par-
enteral priming of the immune system may allow the gut-
associated lymphoid tissue to react successfully to the small
amounts of antigen delivered during oral immunization and
thus decrease the possibility of inducing oral immunotolerance
to plant-based and other orally delivered vaccine antigens. Our
studies support these recent findings by demonstrating that
parenteral priming of mice with intimin purified from trans-
genic plant cells can assist in the development of an intimin-
specific fecal immune response when these mice are subse-
quently boosted with oral feeding of the same intimin-
expressing transgenic plant material. Furthermore, in this
study mice that were parenterally primed and then given an
oral booster showed a statistically significant decrease in the
duration of colonization by wild-type E. coli O157:H7 upon
challenge (P  0.002; log-rank test). Mice immunized entirely
by oral feeding did exhibit a reduction in the duration of
colonization versus unimmunized mice, but the reduction was
not statistically significant. These results suggest that a combi-
nation of vaccination strategies with a vaccine antigen pro-
duced in and delivered by transgenic plants can function in
inducing beneficial, specific immune responses. Further studies
FIG. 3. Duration of E. coli O157:H7 colonization in mice immunized with Int261. The same groups of mice as those shown in Table 4 were
challenged with wild-type E. coli O157:H7. Mice from both groups A and F () showed a statistically significant (P  0.002; log-rank test) reduction
in the duration of colonization compared to group B. No other groups demonstrated a statistically significant reduction compared to group B.
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are needed to determine whether an oral-only immunization
route would suffice if the antigen levels in the plant material or
the number of doses delivered were increased so as to induce
an immune response sufficient to result in a reduction in the
duration of bacterial colonization. Such approaches might
eliminate the requirement for priming by parenteral injection
of intimin.
Our discovery that nonglycosylated bacterial proteins can be
glycosylated in transgenic plant systems highlights an issue
previously not reported in other studies of vaccine antigen
expression in transgenic plants. We found that the glycosyla-
tion of Int261 expressed in NT-1 cells adversely affected the
immunogenicity of the molecule and resulted in an aberrant
immune response that was unable to block adherence of E. coli
O157:H7. Although the addition of a plant-specific signal pep-
tide increased the vaccine antigen expression levels in the plant
cells, the signal peptide may have caused the protein to be
glycosylated in the plant expression system by trafficking the
newly expressed protein directly into the endoplasmic reticu-
lum, where it would be more accessible to the glycosylation
pathways in the Golgi apparatus. The removal of the plant-
specific signal peptide from the Int261 plant expression con-
structs resulted in decreased protein expression but appeared
to produce an unglycosylated protein. Our experience empha-
sizes one of the challenges involved in the successful produc-
tion of bacterial vaccine antigens in transgenic plant systems.
Our finding that these transgenic cells synthesize Int261 in a
conformation that is immunologically equivalent to the native
protein underscores the feasibility of transgenic plant-based
systems for expression and delivery of oral vaccines. For fur-
ther vaccine development, we plan to express a signal se-
quence-free Int261 construct in a whole plant, perhaps by use of
recently developed chloroplast transformation and expression
models (19) that maximize protein expression and minimize
protein modification (such as glycosylation). The selected plant
system will likely be alfalfa because it is compatible with oral
administration to cattle and is amenable to both nuclear and
chloroplast transformation methods. Debate still exists as to
whether feedlot food type, holding pen cleanliness, or water
quality management would offer the benefit of reducing EHEC
O157:H7 colonization levels in cattle (9, 28, 39). One might
hypothesize that removing or reducing environmental sources
of EHEC O157:H7 infection, such as soiled bedding or con-
taminated water sources, would reduce the prevalence of
EHEC O157:H7 in cattle. Unfortunately, these hypotheses
have not been adequately tested. However, the notion that
reduction of sources of EHEC O157:H7 infection and contam-
ination would reduce not only the prevalence of EHEC
O157:H7 in cattle, but also the risk of human infection through
other environmental sources such as drinking or recreational
water and fruits and vegetables, has strong intuitive appeal. We
believe that the use of transgenic plants for the production and
delivery of an EHEC O157:H7 vaccine for cattle, alone or in
conjunction with other potential control methods (5), could
lead to a significant decrease in the level of colonization or
percentage of cattle infected with pathogenic E. coli O157:H7.
Such a reduction will likely translate into a decline in beef
carcass and environmental contamination by E. coli O157:H7
and a decrease in transmission of the bacterium to humans.
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